Payment overview · 2025
General Payments
$78.04
3 reported records · 2 companies
Healthcare provider profile · identity verified
James Joseph Mcconnell, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WYTHEVILLE, VA · NPI 1326027012
Verified facts
What the public records show
CMS Open Payments records show James Joseph Mcconnell, MD received $78.04 in general payments during 2025 across 3 reported records.
Exact Sciences Corporation accounted for 65.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.82 | 65.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.22 | 34.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $78.04 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $50.82 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 396 | 41 |
| Gabapentin | Gabapentin | 376 | 69 |
| Lisinopril | Lisinopril | 245 | 66 |
| Trazodone Hcl | Trazodone Hcl | 230 | 42 |
| Alprazolam | Alprazolam | 213 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 207 | 54 |
| Tramadol Hcl | Tramadol Hcl | 184 | 20 |
| Furosemide | Furosemide | 180 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 168 | 43 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 168 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 140 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 140 | 16 |
| Famotidine | Famotidine | 136 | 34 |
| Potassium Chloride | Potassium Chloride | 136 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 34 |
| Omeprazole | Omeprazole | 130 | 28 |
| Diazepam | Diazepam | 128 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 26 |
| Montelukast Sodium | Montelukast Sodium | 123 | 28 |
| Atorvastatin Calcium | Atorvastatin Calcium | 120 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 30 |
| Lorazepam | Lorazepam | 101 | 14 |
| Mirtazapine | Mirtazapine | 100 | 21 |
| Allopurinol | Allopurinol | 95 | 24 |
| Metformin Hcl | Metformin Hcl | 93 | 29 |
| Promethazine Hcl | Promethazine Hcl | 90 | 12 |
| Carvedilol | Carvedilol | 87 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 23 |
| Eliquis | Apixaban | 87 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 16 |
| Ozempic | Semaglutide | 85 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 22 |
| Losartan Potassium | Losartan Potassium | 81 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 15 |
| Simvastatin | Simvastatin | 77 | 22 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 70 | 18 |
| Meloxicam | Meloxicam | 69 | 21 |
| Baclofen | Baclofen | 67 | 12 |
| Clonazepam | Clonazepam | 58 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 58 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 56 | 17 |
| Sertraline Hcl | Sertraline Hcl | 55 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 11 |
| Levetiracetam | Levetiracetam | 53 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 23 |
| Prednisone | Prednisone | 47 | 26 |
| Fluconazole | Fluconazole | 46 | 19 |
| Pregabalin | Pregabalin | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | 12 |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 41 | 11 |
| Cefdinir | Cefdinir | 39 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Amoxicillin | Amoxicillin | 36 | 18 |
| Spironolactone | Spironolactone | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 33 | 19 |
| Topiramate | Topiramate | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 17 |
| Metolazone | Metolazone | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Oxycontin | Oxycodone Hcl | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Belbuca | Buprenorphine Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 12 |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Buprenorphine | Buprenorphine | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 16 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Alprazolam Er | Alprazolam | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Sodium Fluoride 5000 Dry Mouth | Fluoride (Sodium) | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Meprobamate | Meprobamate | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nucynta | Tapentadol Hcl | 11 | suppressed |
| Prevalite | Cholestyramine | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Triazolam | Triazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $78.04 · 3 records | Exact Sciences Corporation | Cologuard Collection Kit, FARXIGA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error